Tohru Ishikawa

TL;DR: Capecitabine, which is finally converted to 5-FU by dThdPase in tumours, should be much safer and more effective than5-FU, and this was indeed the case in the HCT116 human colon cancer and the MX-1 breast cancer xenograft models.

TL;DR: The results suggest that Taxol might indirectly elevate TNFalpha in tumor cells, which in turn up-regulated dThdPase in the tumor cells in the WiDr cancer xenograft model, and enhance the efficacy of capecitabine and 5'-dFUrd.

TL;DR: Compared the efficacy of capecitabine and 5-FUra at their maximum tolerated doses in CXF280, HCT116, COLO205, and WiDr human colon cancer xenograft models, and measured subsequent 5'-FUra and 5'-dFUrd levels in tumors and in the plasma and muscle, cape citabine might show its high efficacy as a result of delivering high levels of 5'FUra selectively to the tumors.

TL;DR: Results indicate that X-ray irradiation might increase dThdPase levels indirectly through the human TNF-alpha in the tumor tissue, and combined modality treatment of cancer patients with cape-citabine and X-Ray irradiation would have greater potential usefulness than conventional radiochemotherapy with 5-FUra.

TL;DR: Results indicate that capecitabine might exert its efficacy through 5-FUra generated in tumor tissues but not through that generated in normal organs, and would be optimized by selecting patients who have tumors with a high ratio of dThdPase to DPD activities.